Categories: News

Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 04, 2021 (GLOBE NEWSWIRE) — Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, will discuss the company’s transformation and growth initiatives at the 39th Annual J.P. Morgan Healthcare Conference at 2:50 p.m. EST on January 11, 2021.

Mr. Diaz will focus on key opportunities to fulfill the company’s mission of improving patient lives by unlocking the power of precision medicine and helping healthcare providers and payers prevent, diagnose and treat disease through the company’s genetic insights. The presentation will be available via a live audio webcast accessible at the following direct link or through the investor information section of Myriad’s website at www.myriad.com.

About Myriad Genetics

Myriad Genetics Inc., is a leading precision medicine company dedicated improving and transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across in specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. For more information, please visit the Company’s website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Media Contact: Investor Contact:
Jared Maxwell Scott Gleason
(801) 505-5027 (801) 584-1143
jmaxwell@myriad.com sgleason@myriad.com

Staff

Recent Posts

Masimo Responds to Politan’s Continuing Misrepresentations

IRVINE, Calif.--(BUSINESS WIRE)--To ensure that Politan lies repeated over and over are not taken as…

41 mins ago

Complete Care Lakeview Announces Name Change to Complete Care Wayne Hills Rehab & Respiratory Center

WAYNE, NJ / ACCESSWIRE / July 15, 2024 / Complete Care Lakeview, a leading provider…

44 mins ago

Modular Medical Announces Proof-of-Concept Study for Personalized Metabolic Therapy utilizing the MODD1 Platform

Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short…

44 mins ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

Testing confirms MIRA's preliminary beliefs regarding potential treatment for neurological and neuropsychiatric disorders MIAMI, FL…

44 mins ago

Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology

ORLANDO, FL / ACCESSWIRE / July 15, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of…

44 mins ago